Inovio Pharmaceuticals, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses), averaging +6.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.07 | not reported | not reported | |
| Q1 FY26 | $-0.30 | $-0.28 | +6.7% | Beat | |
| Q4 FY25 | not reported | $0.31 | not reported | not reported | Q4 FY25 call |
Back to INO overview · INO holders · INO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.